GHK-Cu vs LL-37 at a glance
| Property | GHK-Cu | LL-37 |
|---|---|---|
| Structure | Tripeptide glycyl-L-histidyl-L-lysine bound to Cu2+ | 37-amino-acid alpha-helical fragment of the cathelicidin precursor hCAP-18 |
| Origin | Isolated from human plasma by Pickart, 1973 | Cleaved from the CAMP gene product hCAP-18, first described by Agerberth et al., 1995 |
| Core mechanism studied | Copper delivery to lysyl oxidase, superoxide dismutase, and ceruloplasmin; regulation of collagen synthesis and MMP activity | Direct disruption of bacterial membranes; angiogenesis via FPRL1; immune signaling via TLR9 |
| Antimicrobial activity | None reported in the literature | Broad spectrum, including E. coli, P. aeruginosa, and MRSA |
| Key animal wound data | Mixed: in vitro fibroblast and rat wound MMP data are consistent; a 2013 irradiated rat flap study found no significant benefit over control | Diabetic ob/ob mouse excisional wounds healed faster with LL-37 delivered by adenoviral vector |
| Human trial data | None published as of 2026 | 34-subject randomized, placebo-controlled trial in venous leg ulcers (Gronberg et al., 2014) |
| Approved drug status | None; sold as a cosmeceutical ingredient | None; limited by rapid proteolysis and a narrow safety margin |
A copper carrier and the body's own antibiotic peptide
GHK-Cu is a tripeptide, glycine-histidine-lysine, that binds copper(II) ions with high affinity. Pickart isolated it from human plasma in 1973 while studying a factor that made aged liver tissue synthesize protein at rates closer to younger tissue. Plasma concentrations run around 200 ng/mL at age 20 and fall to roughly 80 ng/mL by age 60, a decline that tracks the slowdown in wound healing seen with age (Pickart, Journal of Biomaterials Science, 2008). The GHK sequence also sits inside the alpha-2 chain of type I collagen, so proteases acting on damaged collagen at a wound site may release it locally as well.
LL-37 starts from an entirely different biological system. It is cleaved from hCAP-18, the product of the CAMP gene, which sits inactive in the secondary granules of neutrophils until proteinase 3 processes it into the mature 37-residue peptide outside the cell (Sorensen et al., Blood, 2001, human neutrophil granule extracts). Bengt Agerberth's group at the Karolinska Institute first described the precursor in 1995, before the peptide was renamed for its two starting leucines and 37-residue length. Once cleaved, LL-37 carries a net positive charge of about +6 and folds into an amphipathic helix that inserts into negatively charged bacterial membranes while mostly sparing human cells.
What GHK-Cu's evidence actually shows
The clearest GHK-Cu data comes from cell culture, not animals. Maquart and colleagues found that GHK-Cu stimulated collagen synthesis in fibroblast cultures starting at concentrations between 10-12 and 10-11 M and peaking at 10-9 M, with no change in cell number across that range, pointing to a direct synthetic effect rather than a proliferative one (Maquart et al., FEBS Letters, 1988, in vitro fibroblast cultures).
A separate study by the same research group tested GHK-Cu directly in rat wounds and found the complex increased both the expression and activation of MMP-2, alongside a rise in its tissue inhibitors TIMP-1 and TIMP-2 (Simeon et al., Journal of Investigative Dermatology, 1999, rat experimental wounds). A follow-up study reproduced the MMP-2 and TIMP effect in fibroblast culture alone, isolating it to a direct action on the cells rather than a wound-specific inflammatory response (Simeon et al., Life Sciences, 2000, in vitro fibroblast cultures). The pattern across both papers reads as regulated matrix turnover rather than unchecked collagen breakdown.
Whole-animal efficacy data is thinner than the cell-culture work implies. A 2013 study tested GHK-Cu gel against a control ointment in rats with irradiated skin flaps, a model of radiation-impaired healing relevant to head and neck surgery patients. After ten days of twice-daily treatment, the flaps showed no significant difference between GHK-Cu and control across flap ischemia, vessel count, or VEGF staining (Parker et al., Otolaryngology-Head and Neck Surgery, 2013, irradiated rat flap model). That null result sits awkwardly next to the strength of the in vitro data, and it rarely appears in promotional summaries of the compound.
No completed human trial of GHK-Cu for wound healing had been published as of 2026. Smaller open-label skin studies report improved collagen production and skin thickness in a cosmeceutical context, but that is not the kind of registered, controlled trial that would settle the wound-healing question directly. The full mechanistic picture, including the gene-expression modeling behind GHK-Cu's broader research reputation, is covered in the GHK-Cu research overview.
What LL-37's evidence actually shows
LL-37's antimicrobial activity is well established in vitro, with published minimum inhibitory concentrations in the low micromolar range against E. coli, Pseudomonas aeruginosa, and methicillin-resistant Staphylococcus aureus. That activity alone separates it from GHK-Cu, but the wound-repair data is where the comparison gets more interesting. Koczulla and colleagues found that LL-37 induces new blood vessel growth through the FPRL1 receptor on endothelial cells, increasing collateral vessel growth in a rabbit hind-limb ischemia model and vessel density in a chick membrane assay (Koczulla et al., Journal of Clinical Investigation, 2003).
In diabetic ob/ob mice, a standard model for impaired wound healing, delivering LL-37 by adenoviral vector to excisional wounds produced faster re-epithelialization and more granulation tissue than untreated controls, an effect the study authors traced to MAPK and PI3K-Akt pathway activation (Carretero et al., Journal of Investigative Dermatology, 2008, diabetic ob/ob mouse model).
LL-37 is also one of the few compounds in this category with a completed human trial. Gronberg and colleagues ran a randomized, placebo-controlled trial of topical LL-37 in 34 patients with hard-to-heal venous leg ulcers, applying 0.5, 1.6, or 3.2 mg/mL twice weekly for four weeks after a three-week placebo run-in (Gronberg et al., Wound Repair and Regeneration, 2014, n=34). Healing rate constants were roughly six times higher than placebo at the 0.5 mg/mL dose and three times higher at 1.6 mg/mL, with mean ulcer area shrinking 68% and 50% at those two doses.
The highest dose tested, 3.2 mg/mL, showed no benefit over placebo at all, a non-monotonic result the authors did not fully explain. No serious adverse events were reported at any dose tested. A fuller account of LL-37's antimicrobial and immune-signaling research sits in the LL-37 research overview.
Why the same repair problem is not the same peptide problem
GHK-Cu's proposed mechanism runs through structural biology. Copper is a required cofactor for lysyl oxidase, the enzyme that cross-links collagen and elastin, and for the antioxidant enzyme Cu/Zn superoxide dismutase. That gives GHK-Cu a mechanistically coherent story for tissue remodeling, one that has held up in cell culture even where the one available whole-animal efficacy trial did not confirm it.
LL-37's mechanism covers more ground at once: direct antimicrobial killing, an alarmin role in recruiting immune cells, and separately an angiogenic and pro-migratory effect on the cells that close a wound. Researchers studying LL-37 for tissue repair are studying a side effect of a peptide whose main job is host defense, which is also where its clinical translation problem starts. It is not a lack of mechanistic plausibility or animal data, both of which exist.
It is rapid degradation by host and bacterial proteases and a narrow window between antimicrobial concentrations and cytotoxicity to human cells, properties that show up again in the Gronberg trial's inverted dose-response curve. GHK-Cu carries no comparable toxicity ceiling in the literature, but it also has not cleared the bar of a registered efficacy trial in living tissue. Neither compound is close to drug approval for wound healing, for different reasons.
Storage, sourcing, and research handling in Indonesia
Both peptides ship to laboratories as lyophilized powder and need reconstitution before use; the reconstitution guide covers bacteriostatic water technique for either one. LL-37's strong positive charge makes it prone to binding plasticware, which can quietly reduce a working solution's concentration if the same tube is reused across dilutions. GHK-Cu's copper complex is comparatively stable in solution but, like any lyophilized peptide, degrades faster once reconstituted and left at Bali or Jakarta's ambient 28 to 33 degrees C than it would in a temperate lab.
Cold-chain integrity from receipt through reconstitution is the practical variable that matters most in a tropical climate, covered in more depth in the lyophilized peptide storage guide for Zone IV humidity conditions. Concentration and draw-volume math for a specific vial of either compound can be run through the dosing calculator. Under BPOM's framework for laboratory materials, both GHK-Cu and LL-37 are handled as research reagents rather than registered pharmaceuticals when supplied to Indonesian labs, and neither has an approved drug indication in any jurisdiction. Zurich Biotech supplies GHK-Cu as part of its copper peptide line.